1. Home
  2. ASST vs BGLC Comparison

ASST vs BGLC Comparison

Compare ASST & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asset Entities Inc. Class B

ASST

Asset Entities Inc. Class B

HOLD

Current Price

$0.87

Market Cap

913.3M

Sector

Technology

ML Signal

HOLD

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$4.17

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASST
BGLC
Founded
2020
2017
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
913.3M
10.1M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
ASST
BGLC
Price
$0.87
$4.17
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$1.50
N/A
AVG Volume (30 Days)
90.3M
201.4K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,512,106.00
$9,465,006.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
125.01
2.21
52 Week Low
$0.78
$2.01
52 Week High
$7.89
$15.60

Technical Indicators

Market Signals
Indicator
ASST
BGLC
Relative Strength Index (RSI) 35.63 37.92
Support Level $0.88 $4.02
Resistance Level $1.04 $4.34
Average True Range (ATR) 0.08 0.26
MACD 0.02 0.00
Stochastic Oscillator 0.09 15.45

Price Performance

Historical Comparison
ASST
BGLC

About ASST Asset Entities Inc. Class B

Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: